Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Briacell Therapeutics Corp T.BCT

Alternate Symbol(s):  BCTX | BCTXW

Healthcare Biotechnology
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.


TSX:BCT - Post by User

Briacell Therapeutics Corp
Bullboard Posts
User Avatar Image
(0)
•••
Comment by howie15on Nov 20, 2011 8:45pm
316 Views
Post# 19252868

RE: RE: ACP drills 23.05 m of 9.85 g/t Au

RE: RE: ACP drills 23.05 m of 9.85 g/t Au insiders are happy they are still buyingNov 19/11 Nov 15/11 Factor, Lynn Indirect Ownership Common Shares 10 - Acquisition in the public market 19,000
.180Nov 18/11 Nov 14/11 Factor, Lynn Indirect Ownership Common Shares 10 - Acquisition in the public market 50,000
.198Nov 18/11 Nov 14/11 Factor, Lynn Indirect Ownership Common Shares 10 - Acquisition in the public market 50,000
.190Nov 18/11 Nov 14/11 Factor, Lynn Indirect Ownership Common Shares 10 - Acquisition in the public market 10,000
.180Nov 2/11 Oct 28/11 Factor, Lynn Indirect Ownership Common Shares 10 - Acquisition in the public market 20,000
.200Nov 2/11 Oct 28/11 Factor, Lynn Indirect Ownership Common Shares 10 - Acquisition in the public market 30,000
.210Nov 2/11 Oct 28/11 Factor, Lynn Indirect Ownership Common Shares 10 - Acquisition in the public market 100,000
.235Nov 2/11 Oct 28/11 Factor, Lynn Indirect Ownership Common Shares 10 - Acquisition in the public market 50,000
.210Oct 23/11 Oct 18/11 Factor, Lynn Indirect Ownership Common Shares 10 - Acquisition in the public market 50,000
.140Oct 23/11 Oct 18/11 Factor, Lynn Indirect Ownership Common Shares 10 - Acquisition in the public market 24,000
.120
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities